气候变化领域集成服务门户(CCPortal): Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial

CCPortal

DOI	10.1016/j.scib.2021.06.002
	Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial
	Wang Y.; Liu Q.-F.; Lin R.; Yang T.; Xu Y.-J.; Mo X.-D.; Huang X.-J.
发表日期	2021
ISSN	20959273
英文摘要	Given that randomized studies testing the long-term impact of antithymocyte globulin (ATG) dosing are scarce, we report the results of an extended follow-up from the original trial. In our prospective, multicenter, randomized trial, 408 leukemia patients 14–65 years of age who underwent haploidentical hematopoietic cell transplantation (haplo-HCT) under our original “Beijing protocol” were randomly assigned one-to-one to ATG doses of 7.5 mg/kg (n = 203, ATG-7.5) or 10 mg/kg (n = 205, ATG-10.0) at four sites. Extended follow-up (median 1968 d (range: 1300–2710 d) indicated comparable 5-year probabilities of moderate-to-severe chronic graft-versus-host disease (GVHD) (hazard ratio (HR): 1.384, 95% confidence interval (CI): 0.876–2.189, P = 0.164), nonrelapse mortality (HR: 0.814, 95% CI: 0.526–1.261, P = 0.357), relapse (HR: 1.521, 95% CI: 0.919–2.518, P = 0.103), disease-free survival (HR: 1.074, 95% CI: 0.783–1.473, P = 0.658), and GVHD-free/relapse-free survival (HR: 1.186, 95% CI: 0.904–1.555, P = 0.219) between groups (ATG-7.5 vs. ATG-10.0). The 5-year rate of late effects did not differ significantly. However, the cytomegalovirus/Epstein-Barr virus-related death rate was much higher in the ATG-10.0 cohort than in the ATG-7.5 cohort (9.8% vs. 1.5%; P = 0.003). In summary, patients undergoing haplo-HCT benefit from 7.5 mg/kg ATG compared to 10.0 mg/kg ATG based on a balance between GVHD and infection control. ATG (7.5 mg/kg) is potentially regarded as the standard regimen in the platform. These results support the optimization of ATG use in the “Beijing Protocol”, especially considering the potential economic advantage in developing countries. © 2021 Science China Press
关键词	Antithymocyte globulin Chronic graft-versus-host disease GVHD-free/relapse-free survival Haematopoietic cell transplantation Haploidentical Late effects
英文关键词	Cytology; Graft vs. host reactions; Grafting (chemical); Grafts; Viruses; Antithymocyte globulin; Cell transplantation; Confidence interval; Graft-versus-host disease; Graft-versus-host disease-free/relapse-free survival; Haploidentical; Hazard ratio; Hematopoietic cell; Hematopoietic cell transplantation; Late effects; Cells
语种	英语
来源期刊	Science Bulletin
文献类型	期刊论文
条目标识符	http://gcip.llas.ac.cn/handle/2XKMVOVA/207602
作者单位	Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, 100044, China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China; Department of Hematology, Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, 350001, China; Department of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, China; Collaborative Innovation Center of Hematology, Peking University, Beijing, 100044, China; Peking-Tsinghua Center for Life Sciences, Beijing, 100871, China
推荐引用方式 GB/T 7714	Wang Y.,Liu Q.-F.,Lin R.,et al. Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial[J],2021.
APA	Wang Y..,Liu Q.-F..,Lin R..,Yang T..,Xu Y.-J..,...&Huang X.-J..(2021).Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial.Science Bulletin.
MLA	Wang Y.,et al."Optimizing antithymocyte globulin dosing in haploidentical hematopoietic cell transplantation: long-term follow-up of a multicenter, randomized controlled trial".Science Bulletin (2021).